Podcast Index
Browse podcasts by category, open recent episodes, and download audio to listen offline.
BioCentury This Week
BioCentury
Accounting Voices
Rob Brown
The Growth Workshop Podcast
Southwestern Family of Podcasts - Southwestern Family of Companies
PR in the Real World
Viva PR
Mad Money w/ Jim Cramer
CNBC
硬核比特--人工智能硬核比特币新闻
Meng
The Employment Law Show
AM640
Valuetainment
Valuetainment
The Conscious Capitalists
Conscious Capitalism
RoofersCoffeeShop
RoofersCoffeeShop
The Money Marketing Podcast
moneymarketing
Abraham Hicks’s Podcast
Abraham Hicks
IMPACTFUL Teamwork
Julia Felton
High Voltage Business Builders Podcast
Neil Twa
美股早咖啡
Meng
Abraham Hicks
Abraham Hicks
Insurance Exam Prep
Ran Chen, EA, CFP®
손에 잡히는 경제
MBC
Membership Geeks Podcast with Mike Morrison
Membership Geeks
36氪·8点1氪
36氪音频
The Colubrid Corruption Podcast
Meteoric Serpents
Real Estate News Today | 2 Min News | The Daily News Now!
The Daily News Now!
PennyWise: Personal Finance & Travel Tips
Lee Enterprises
China Watch
The Epoch Times
NTD Evening News
NTD Evening News
Daily Market Download
Daily Market Download
TBPN
John Coogan & Jordi Hays
Hidden Forces
Demetri Kofinas
富邦期貨：富邦期權通
富邦期貨
One Rental At A Time
Michael Zuber
Embracing Digital Transformation
Dr. Darren Pulsipher
The Influential Advisor Podcast
Paul G. McManus and Gabe McManus
Behind the Book Cover
Anna David
The Weekly Take from CBRE
CBRE
Talking Trading | Australian Sharemarket Strategies, Education & Trading Psychology
Created by best-selling author and trader - Louise Bedford
Hacking Your Health
Hacking Your Health
Der Pflegedeutsch Podcast
Britta Salm
Business
BioCentury
New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts re...
AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the takeo...
Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for fresh biotech paper on NASDAQ, including the $...
Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too.From AI to NAMs to starting a Phase I trial in the U.S., BioCentury’s 3rd Grand Round...
FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdi...
Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data...
At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field’s approach to t...
Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin disc...
China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s analysts, along with special guests Detlev Mennerich, head of Boehringer I...
Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commissioner shifting the question from whether he will be fired to when. On the lates...
UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therapeutics, one of the leading T cell engager companies. On the latest BioCe...
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make ...
Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting in San Diego as biotechs unveiled their latest preclinical and first-i...
The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon become the largest biotech IPO ever on NASD...
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Australia, China and the U.K. On the latest BioCentury This Week podcast, ...
Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but will the Mideast conflict halt biotech’s recovery? On the latest BioCentur...
Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed to de-risk assets. The new momentum from Asia, in particular China, has added a f...
A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podcast, BioCentury’s Paul Bonanos assesses last week’s deals by Merck, which is lay...
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how the company has built...
Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to debut on NASDAQ — but will geopolitical tensions and war in the Middle East scut...
Fill in the form below. Make sure to select both Country and Genres.
Send us a message below. We will get back to you within 24 hours.